BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.

Rita Lobo,Andreas Obruca,Ermanno Greco,Peter Fedorcsak,Anja Pinborg,Michael Schenk,Celia J Parkyn,Ben Cohlen,Foad Azem,Einat Shalom-Paz,Moritz Suerdieck,Moritz B Suerdieck,Omar Josef Shebl,Ben Cohlen,Philippe Pinton,Bernadette Mannaerts,Yoel Shufaro,Jesper Smeenk,Michael Häberle,Terje Soerdal,Anja Pinborg,Eleonora Porcu,Erling Ekerhovd,Talia Eldar-Geva

doi:10.1093/humrep/deae092

BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.

Rita Lobo, Andreas Obruca + Show 22 more

https://doi.org/10.1093/humrep/deae092

Copy DOI

Export

Save

Cite

Journal: Human reproduction (Oxford, England)	Publication Date: May 9, 2024
Citations: 1	License type: CC BY 4.0

Affiliation: Tel Aviv University, Elisabeth-TweeSteden Ziekenhuis, Copenhagen University Hospital

#Ovarian Stimulation Cycle #GnRH Agonist Protocol #GnRH Antagonist Protocol #Agonist Protocol #GnRH Antagonist #Ovarian Cycle #Follitropin Delta #GnRH Agonist #Antagonist Protocol #Ovarian Stimulation

Abstract
Full-Text
Similar Papers

Abstract

Listen

BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Human reproduction (Oxford, England)

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.